Artivion Inc (AORT)vsNovartis AG ADR (NVS)
AORT
Artivion Inc
$20.12
-3.45%
HEALTHCARE · Cap: $971.11M
NVS
Novartis AG ADR
$148.38
-2.52%
HEALTHCARE · Cap: $289.19B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 12235% more annual revenue ($56.58B vs $458.69M). NVS leads profitability with a 23.9% profit margin vs 2.5%. NVS appears more attractively valued with a PEG of 4.11. NVS earns a higher WallStSmart Score of 49/100 (D+).
AORT
Hold41
out of 100
Grade: D
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-31.9%
Fair Value
$30.41
Current Price
$20.12
$10.29 premium
Margin of Safety
-65.2%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 80.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
AORT profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.26 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 41/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?